US Patent 9956435 Injectable botulinum toxin formulations
Patent 9956435 was granted and assigned to Revance Therapeutics, Inc. on May, 2018 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
December 28, 2009
Date of Patent
May 1, 2018
Patent Application Number
13141935
Patent Citations Received
Patent Jurisdiction
Patent Number
Patent Primary Examiner
Find more entities like US Patent 9956435 Injectable botulinum toxin formulations
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.